Showing 5981-5990 of 9662 results for "".
Part 2, 1726 nm lasers: All about the AviClear and Accure devices from clinical trial to today, including pulsing protocols and pain control methods
https://practicaldermatology.com/videos/scientifically-speaking/1726-nm-lasers-five-dermatologists-discuss-the-lasers-benefits-and-drawbacks-for-treating-acne-and-other-skin-conditions/24340/Chapter 2 of 7: David Goldberg, MD, from New York, Emil Tanghetti, MD, from Sacramento, Jordan Wang, MD, from Philadelphia and New York and Naz Saedi, MD, from Philadelphia talk about the AviClear and Accure devices from clinical trial to today, including pulsing protocols and pain control methods.What’s on the Horizon for Acne?
https://practicaldermatology.com/conferences/maui-derm-2024/whats-on-the-horizon-for-acne/20254/Julie C. Harper, MD, explains her Maui Derm presentation, including an overview of the many potential treatments for acne that are on the horizon, such as a possible acne vaccine.How Combination Treatments Can Address Unmet Needs
https://practicaldermatology.com/conferences/maui-derm-2024/how-combination-treatments-can-address-unmet-needs/20243/Suneel Chilukuri, MD, talks with Chief Medical Editor Neal Bhatia, MD, about the progress cosmetic dermatology has made to fill previous gaps in options to address areas such as the chest, neck, and knees, especially with the range of advanced devices that often produce even better results when usedHow to Discuss Isotretinoin’s Safety Profile With Acne Patients
https://practicaldermatology.com/conferences/maui-derm-2024/how-to-discuss-isotretinoins-safety-profile-with-acne-patients/20237/Acne Symposium moderator Guy Webster, MD, PhD, clinical professor of dermatology at Thomas Jefferson University, explains how he helps adolescent patients with the most severe cases of acne manage the potential side effects of isotretinoin.Aesthetic Advances: New Technology
https://practicaldermatology.com/conferences/cosmetic-surgery-forum-2022/aesthetic-advances-new-technology/20160/Suneel Chilukuri, MD discusses the benefits of some of the new devices he’s using to improve outcomes for his aesthetic patients. He says BTL’s Emface offers him the ability to tighten and tone the facial muscles and lift neck muscles. He describes the benefits of the Sylfirm X RF microneedling systDermWireTV: Sotyktu Approval, Cetaphil at 75, Psoriasis/Depression Link
https://practicaldermatology.com/topics/psoriasis/dermwiretv-sotyktu-approval-cetaphil-at-75-psoriasisdepression-link/20138/FDA has approved Bristol Myers Squibb’s Sotyktu (deucravacitinib) for the oral treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. April Armstrong, MD discusses the first TYK-2 inhibitor approved for psoriasis. As Cetaphil (Galderma)AK Burden and Progression Risk
https://practicaldermatology.com/topics/skin-cancer-photoprotection/ak-burden-and-progression-risk/20134/Individuals with chronic sun damage are at higher risk of developing AK lesions. It is therefore essential that dermatologists emphasize early sun protection recommendations and address progression risks of AK with their patients. Faced with increasing burden of skin cancers, Joel L. Cohen, MD and AHormonal Acne Treatment Options
https://practicaldermatology.com/conferences/maui-derm-2022/hormonal-acne-treatment-options/20053/All acne is hormonal acne, says Julie C. Harper, MD. She discusses her approach to treating acne in preadolescents, adolescents, and male and female patients. From the role of oral contraceptives for women to the new topical clascoterone option, she says there are a number of safe and effective treaManaging Patients with Atypical Nevi and Melanoma
https://practicaldermatology.com/topics/skin-cancer-photoprotection/managing-patients-with-atypical-nevi-and-melanoma/19982/Monitoring patients with several atypical nevi who are at high risk for melanoma is very challenging. Steven Q. Wang, MD offers tips for improving diagnostic accuracy and discusses the role of dermoscopy in detecting melanoma as well as non-melanoma skin cancers at much earlier rates.DermWireTV: Cosentyx for Kids; Anifrolumab for SLE, Tremfya in PsA at EULAR
https://practicaldermatology.com/topics/psoriasis/dermwiretv-cosentyx-for-kids-anifrolumab-for-sle-tremfya-in-psa-at-eular/19948/FDA has approved Cosentyx (secukinumab) from Novartis for patients as young as six years old. The 2nd Annual San Diego Dermatology Symposium kicks off as a live Virtual Experience next Friday. A post-hoc analysis of pooled data from the TULIP Phase 3 clinical trials shows that anifrolumab improves